Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation

NCT03110900 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT03110900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03110900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Lead sponsor
University of Arkansas
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2017
Completion date
April 4, 2018
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

agitation,psychomotor, haloperidol causing adverse effects in therapeutic use, lorazepam causing adverse effects in therapeutic use, loxapine causing adverse effects in therapeutic use